Abstract
An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10-12 M to 5 x 10-14 M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.
| Original language | English |
|---|---|
| Pages (from-to) | 203-211 |
| Number of pages | 9 |
| Journal | British Journal of Haematology |
| Volume | 81 |
| Issue number | 2 |
| Publication status | Published - 1992 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Ber-H2 (anti-CD30)-saporin immunotoxin : A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation. / Tazzari, P. L.; Bolognesi, A.; De Totero, D.; Falini, B.; Lemoli, R. M.; Soria, M. R.; Pileri, S.; Gobbi, M.; Stein, H.; Flenghi, L.; Martelli, M. F.; Stirpe, F.
In: British Journal of Haematology, Vol. 81, No. 2, 1992, p. 203-211.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ber-H2 (anti-CD30)-saporin immunotoxin
T2 - A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation
AU - Tazzari, P. L.
AU - Bolognesi, A.
AU - De Totero, D.
AU - Falini, B.
AU - Lemoli, R. M.
AU - Soria, M. R.
AU - Pileri, S.
AU - Gobbi, M.
AU - Stein, H.
AU - Flenghi, L.
AU - Martelli, M. F.
AU - Stirpe, F.
PY - 1992
Y1 - 1992
N2 - An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10-12 M to 5 x 10-14 M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.
AB - An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10-12 M to 5 x 10-14 M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.
UR - http://www.scopus.com/inward/record.url?scp=0026643025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026643025&partnerID=8YFLogxK
M3 - Article
C2 - 1322690
AN - SCOPUS:0026643025
VL - 81
SP - 203
EP - 211
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -